Welcome to the Working Group on New TB Drugs Blog
Posted in Announcements, Funding Opportunities, TB Prevention and Control Strategies
Call for TB REACH Wave 3 Proposals
TB REACH is currently accepting applications for Wave 3. The deadline for submitting proposals for Wave 3 is 17 September 2012.
InTB Winners Announced!
The inaugural InTB contest winners are announced in three categories: Overall Winner, Advocacy Winner, and Fan Favorite. Thank you to all entrants. Keep submitting your innovations to grow the InTB library!
TB R&D Weekly Update: Janssen Seeks Approval from FDA for Bedaquiline
This week it was announced the Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson & Johnson, filed a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for their drug Bedaquiline (a.k.a. TMC-207).
Posted in Faces of TB, TB R&D Spotlight Interviews, Video, Voices from the Fight to Stop Tuberculosis
Integrating TB and HIV Services at the Community Level
This week we highlight an interview with Jeannine Uwimana, a public health specialist from the University of the Western Cape and TB/HIV Care Association in South Africa. She discusses her work in developing models for community-based programs to enhance TB and HIV collaborative activities.
Posted in Announcements, TB Diagnostics, TB News, TB Prevention and Control Strategies
Breaking news from the Stop TB Partnership
The Stop TB Partnership made two exciting announcements today: 1. US$ 40 million committed to roll-out of Xpert and 2. Dramatic results from TB REACH mHealth project make case for wider implementation.
TB R&D Weekly Update: Delamanid Shows Promise against Multidrug-Resistant TB
This week, efficacy data from the recently completed Phase 2 randomized placebo-controlled trial in MDR patients evaluating delamanid with background treatment compared to placebo with background treatment was published yesterday in the New England Journal of Medicine. Delamanid (OPC-67683) is a new agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis. The abstract and overview of news coverage are presented, as well as, additional links to TB R&D news.
TB R&D Weekly Update: Expanding Our Options for TB Treatment
For this week’s update, we will highlight three recent articles that look at repurposing and optimizing drugs already on the market or looking at novel targets and drug classes for TB. Additional links to TB R&D news are included.
Watch Video from the World TB Day Congressional Briefing
A briefing and update on tuberculosis (TB), a disease that is curable but still takes the lives of 4,000 people each day and is the number one killer of people living with HIV. Links to video included.
Posted in Faces of TB, TB Patient Perspective, TB R&D Spotlight Interviews, TB Stigma, Voices from the Fight to Stop Tuberculosis, WGND Podcast Series
Community Engagement through Drama
Dr. Gill Black is the co-founder and Director of Health and Welfare at The Sustainable Livelihoods Foundation (SLF). In this inteview, we discuss with Dr. Black one of SLF’s groundbreaking projects that uses drama to engage local communities around issues related to TB and HIV/AIDS.
TB R&D Update: Strategies for Early and Late Stage Drug Development
This week, we are highlighting two articles published online in the Journal of Infectious Diseases in March. The first article by Coxon, et al., looks at the benefits and limitations of the two main approaches to compound discovery for TB, target-based and phenotypic-based. The second article by Phillips, et al., would like TB clinical trialists to consider new strategies or designs for evaluating TB drug regimens which could alleviate a bottleneck as new drugs and consequently new potential drug combinations move into clinical testing. Additional links to TB R&D publications and news are included.
-
Toppix TB News- TB, a neglected disease in Uganda 15 May 2013
- Dr. John: Medications, T.B, tinnitus 8 May 2013
- U.S. non-profit group to build tuberculosis center in Pyongyang 4 May 2013
- Predictors of tuberculosis (TB) and antiretroviral (ARV) medication... 26 Apr 2013
- Multidrug-resistant tuberculosis (MDR-TB): an interview with Dr.... 26 Apr 2013
